The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...

City AM columnist Mark Kleinman tackles Rachel Reeves' budget plans, M&A and the investment summit in his weekly column.

DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

EU regulators are considering withdrawing market authorizations for two hair loss and enlarged prostate treatments over ...

The once-hot Silicon Valley startup has seen its stock’s value decline 99% and is struggling to survive. That has put the ...